AstraZeneca has raised its revenue guidance for the full year after strong sales of its Evusheld Covid-19 antibody treatment and drugs to treat cancer and rare diseases.
在Evusheld新冠抗體治療劑和治療癌症和罕見疾病的藥物銷售強勁後，阿斯特捷利康上調了全年營收指引。
您已閱讀7%（218字），剩餘93%（3107字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。